Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: 1. 1 Cyclophosphamide is indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases 1. 1 Minimal Change Nephrotic Syndrome in Pediatric Patients 1. 2 Limitations of Use: Cyclophosphamide Capsules are indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Capsules, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Capsules are indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use:.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases 1. 1 Minimal Change Nephrotic Syndrome in Pediatric Patients 1. 2 Limitations of Use: Cyclophosphamide Capsules are indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Capsules, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Capsules are indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use:.

Indication: BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. 1 Waldenström's macroglobulinemia (WM). 2 Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one antien dashCD20-based regimen. 3 Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 4 Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. 5 BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14. 1) BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) [see Clinical Studies (14. 2) BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one antien dashCD20-based regimen. 3) BRUKINSA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [see Clinical Studies (14. 4) BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.